title: The EMAS 2006/2007 update on clinical recommendations on postmenopausal hormone therapy.
abstract: This new statement from EMAS presents the findings reported in recent publications from both WHI trials. In general, the reports do not necessitate a revision of the current EMAS advice. They provide further insight into the ongoing controversy around the possibility that hormone therapy (HT) in the form of estrogen (E) alone or estrogen-progestogen (EP) may influence risk of breast cancer differently. They confirm that the increase of breast cancer diagnosis under EP is only significant after a cumulative use of more than 5 years but suggest that there is no increased risk by E within 10 years.
authors.affiliation: Frederiksberg Hospital, Department of Ob/Gyn, 2000 Copenhagen F, Denmark.
authors.forename: Anne
authors.initials: A
authors.lastname: Gompel
authors.forename: David
authors.initials: D
authors.lastname: Barlow
authors.forename: Serge
authors.initials: S
authors.lastname: Rozenberg
authors.forename: Sven O
authors.initials: SO
authors.lastname: Skouby
mesh_terms: D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000379:methods*; D004966:Estrogens, Conjugated (USP) / Q000009:adverse effects; D005060:Europe; D005260:Female; D006801:Humans; D017410:Practice Guidelines as Topic; D012955:Societies, Medical; D016387:Women's Health
chemical_list: D004966:Estrogens, Conjugated (USP)